

Jiahao Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6887473/publications.pdf>

Version: 2024-02-01

7
papers

237
citations

1478505

6
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

216
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF1 α /SLC7A11 pathway. <i>Cell Proliferation</i> , 2022, 55, e13158.	5.3	130
2	Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 673.	3.5	52
3	A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 619.	3.5	16
4	Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. <i>Immunotherapy</i> , 2020, 12, 1067-1075.	2.0	15
5	Histamine2-Receptor Antagonists, Proton Pump Inhibitors, or Potassium-Competitive Acid Blockers Preventing Delayed Bleeding After Endoscopic Submucosal Dissection: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1055.	3.5	11
6	Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer. <i>Immunotherapy</i> , 2020, 12, 705-713.	2.0	7
7	Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1237-1246.	2.0	6